<DOC>
	<DOCNO>NCT02008214</DOCNO>
	<brief_summary>Current Hepatitis C virus ( HCV ) treatment consist combination interferon alpha 2a ( IFN-alpha 2a ) plus ribavirin ( RBV ) provide sustained virologic response ( SVR ) 54 56 % HCV monoinfected patient response even low HIV-HCV coinfected patient . A previous study HCV monoinfected patient show addition pentoxyfylline ( PTX ) treatment scheme base interferon-alfa ribavirin increase SVR 25 % , although know effect obtain HCV-HIV coinfected patient . On hand , factor host genetics , prove influence treatment response HCV infect patient . The best described genetic factor far interleukin 28B ( IL28B ) polymorphism rs12979860 , cytosine-cytosine ( CC ) genotype provide almost twice increase SVR rest genotype . Therefore , randomize , double blind study assess efficacy pentoxyfylline addition treatment scheme base interferon-alfa ribavirin chronic HCV genotype 1 , co-infected HIV-1 positive subject , consider IL28B polymorphism rs12979860 . HIV-HCV coinfected subject currently receive Highly active antiretroviral therapy ( HAART ) , least 8 month undetectable HIV viral load T helper cell count 200 high include . Patients randomize one two group : - Group A : IFN alpha 2a + RBV + PTX - Group B : IFN alpha 2a + RBV + placebo Patients follow primary outcome 72 ( rapid responder ) 96 week ( non rapid response ) . Outcome measure follow : - SVR rate 24 week end treatment - Grade Hepatic fibrosis baseline end treatment , measure transient elastography AST platelet ratio index ( APRI index ) - IL28B rs12979860 genotype The study hypothesis addition PTX treatment scheme base IFN-alfa2a RBV chronic HCV genotype 1 , co-infected HIV-1 positive subject improve SVR rate fibrosis progression irrespectively IL28B rs12979860 genotype .</brief_summary>
	<brief_title>Efficacy PTX+IFN Alpha+ RBV Hepatitis C Virus Coinfected HIV Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>HIV/HCV coinfected patient 18 65 year old currently receive HAART nonpregnant woman HIV infection control : undetectable viral load ( &lt; 40 copies/mL ) least 8 month T helper cell count 200 cells/Î¼L contraindication IFN alpha2a , RBV PTX treatment sign inform consent form laboratory parameter within acceptable range Women present positive pregnancy test study Patients reason longer wish receive IFN alpha2a , RBV PTX treatment Serious adverse event prevent continue IFN alpha2a , RBV PTX treatment ; severe neutropenia , severe thrombocytopenia severe anemia Presence opportunistic infection malignancy require treatment drug interact IFN alpha2a , RBV PTX Patients fail adhere treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pentoxifylline</keyword>
	<keyword>Sustained virologic response</keyword>
	<keyword>Hepatic fibrosis</keyword>
</DOC>